← Eichor
Condition: Metastatic Locally Pancreatic Ductal Adenocarcinoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Metastatic Locally Pancreatic Ductal Adenocarcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06405490AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
Phase 1 · 3 location(s) · Avacta Life Sciences Ltd · NCT07454642Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With
Phase 1/Phase 2 · 10 location(s) · Anocca AB · NCT07145450Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07480928Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxe
Phase 1/Phase 2 · 4 location(s) · Onconic Therapeutics Inc. · NCT05257993Targeted Pathway Inhibition in Patients With Pancreatic Cancer
EARLY_Phase 1 · 1 location(s) · OHSU Knight Cancer Institute · NCT04005690Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07627711A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma
Phase 2 · 1 location(s) · Qilu Pharmaceutical Co., Ltd. · NCT06261359Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreat
Phase 2 · 6 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT07483983Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410494Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors
Phase 1 · 1 location(s) · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · NCT07589205A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Phase 1 · 10 location(s) · Dren Bio · NCT06999187A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerabili
Phase 1/Phase 2 · 10 location(s) · ITM Oncologics GmbH · NCT05706129Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Meta
Phase 2 · 1 location(s) · The University of Texas Health Science Center, Houston · NCT06831136A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarci
Phase 1/Phase 2 · 4 location(s) · Shenzhen Majory Biotechnology Co., Ltd. · NCT07235202The KN510713 Study in Combination With mFOLFIRINOX
Phase 1/Phase 2 · 1 location(s) · New Cancer Cure-Bio Co.,Ltd. · NCT07114861Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer
Phase N/A · 1 location(s) · University of California, San Francisco · NCT06600906OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
EARLY_Phase 1 · 1 location(s) · OHSU Knight Cancer Institute · NCT07089940A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Phase 1 · 20 location(s) · Astellas Pharma Inc · NCT07094204NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer
Phase 1/Phase 2 · 1 location(s) · West China Hospital · NCT07595172
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.